公式に出てますね
European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection
h ttps://news.bms.com/press-release/corporatefinancial-news/european-commission-approves-bristol-myers-squibbs-opdivo-ni-0
公式に出てますね
European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection
h ttps://news.bms.com/press-release/corporatefinancial-news/european-commission-approves-bristol-myers-squibbs-opdivo-ni-0